322 related articles for article (PubMed ID: 33260535)
1. Optimizing PSMA Radioligand Therapy for Patients with Metastatic Castration-Resistant Prostate Cancer. A Systematic Review and Meta-Analysis.
von Eyben FE; Bauman G; von Eyben R; Rahbar K; Soydal C; Haug AR; Virgolini I; Kulkarni H; Baum R; Paganelli G
Int J Mol Sci; 2020 Nov; 21(23):. PubMed ID: 33260535
[TBL] [Abstract][Full Text] [Related]
2. A Systematic Review and Meta-analysis of the Effectiveness and Toxicities of Lutetium-177-labeled Prostate-specific Membrane Antigen-targeted Radioligand Therapy in Metastatic Castration-Resistant Prostate Cancer.
Sadaghiani MS; Sheikhbahaei S; Werner RA; Pienta KJ; Pomper MG; Solnes LB; Gorin MA; Wang NY; Rowe SP
Eur Urol; 2021 Jul; 80(1):82-94. PubMed ID: 33840558
[TBL] [Abstract][Full Text] [Related]
3. PSMA-targeted radioligand therapy in prostate cancer: current status and future prospects.
Parghane RV; Basu S
Expert Rev Anticancer Ther; 2023; 23(9):959-975. PubMed ID: 37565281
[TBL] [Abstract][Full Text] [Related]
4.
Ballal S; Yadav MP; Sahoo RK; Tripathi M; Dwivedi SN; Bal C
Prostate; 2021 Jun; 81(9):580-591. PubMed ID: 33905559
[TBL] [Abstract][Full Text] [Related]
5.
Sadaghiani MS; Sheikhbahaei S; Werner RA; Pienta KJ; Pomper MG; Gorin MA; Solnes LB; Rowe SP
Prostate; 2022 May; 82(7):826-835. PubMed ID: 35286735
[TBL] [Abstract][Full Text] [Related]
6. Clinical Outcomes of
Barber TW; Singh A; Kulkarni HR; Niepsch K; Billah B; Baum RP
J Nucl Med; 2019 Jul; 60(7):955-962. PubMed ID: 30683770
[No Abstract] [Full Text] [Related]
7. Predictors of Overall and Disease-Free Survival in Metastatic Castration-Resistant Prostate Cancer Patients Receiving
Sathekge M; Bruchertseifer F; Vorster M; Lawal IO; Knoesen O; Mahapane J; Davis C; Reyneke F; Maes A; Kratochwil C; Lengana T; Giesel FL; Van de Wiele C; Morgenstern A
J Nucl Med; 2020 Jan; 61(1):62-69. PubMed ID: 31101746
[TBL] [Abstract][Full Text] [Related]
8. Third-line treatment and
von Eyben FE; Roviello G; Kiljunen T; Uprimny C; Virgolini I; Kairemo K; Joensuu T
Eur J Nucl Med Mol Imaging; 2018 Mar; 45(3):496-508. PubMed ID: 29247284
[TBL] [Abstract][Full Text] [Related]
9. Treatment Outcome, Toxicity, and Predictive Factors for Radioligand Therapy with
Heck MM; Tauber R; Schwaiger S; Retz M; D'Alessandria C; Maurer T; Gafita A; Wester HJ; Gschwend JE; Weber WA; Schwaiger M; Knorr K; Eiber M
Eur Urol; 2019 Jun; 75(6):920-926. PubMed ID: 30473431
[TBL] [Abstract][Full Text] [Related]
10. PSMA targeted radioligandtherapy in metastatic castration resistant prostate cancer after chemotherapy, abiraterone and/or enzalutamide. A retrospective analysis of overall survival.
Rahbar K; Boegemann M; Yordanova A; Eveslage M; Schäfers M; Essler M; Ahmadzadehfar H
Eur J Nucl Med Mol Imaging; 2018 Jan; 45(1):12-19. PubMed ID: 29026946
[TBL] [Abstract][Full Text] [Related]
11. Evolving role of
Satapathy S; Sood A; Das CK; Mittal BR
Prostate Cancer Prostatic Dis; 2021 Sep; 24(3):880-890. PubMed ID: 33746213
[TBL] [Abstract][Full Text] [Related]
12. TheraP: a randomized phase 2 trial of
Hofman MS; Emmett L; Violet J; Y Zhang A; Lawrence NJ; Stockler M; Francis RJ; Iravani A; Williams S; Azad A; Martin A; McJannett M; ; Davis ID
BJU Int; 2019 Nov; 124 Suppl 1():5-13. PubMed ID: 31638341
[TBL] [Abstract][Full Text] [Related]
13. Radioligand Therapy With
Yadav MP; Ballal S; Sahoo RK; Dwivedi SN; Bal C
AJR Am J Roentgenol; 2019 Aug; 213(2):275-285. PubMed ID: 30995089
[No Abstract] [Full Text] [Related]
14. Visceral Metastases as Predictors of Response and Survival Outcomes in Patients of Castration-Resistant Prostate Cancer Treated With 177Lu-Labeled Prostate-Specific Membrane Antigen Radioligand Therapy: A Systematic Review and Meta-analysis.
Satapathy S; Mittal BR; Sood A
Clin Nucl Med; 2020 Dec; 45(12):935-942. PubMed ID: 32956129
[TBL] [Abstract][Full Text] [Related]
15.
von Eyben FE; Kairemo K; Paller C; Hoffmann MA; Paganelli G; Virgolini I; Roviello G
Biomedicines; 2021 Aug; 9(8):. PubMed ID: 34440246
[TBL] [Abstract][Full Text] [Related]
16. Poor Outcomes for Patients with Metastatic Castration-resistant Prostate Cancer with Low Prostate-specific Membrane Antigen (PSMA) Expression Deemed Ineligible for
Thang SP; Violet J; Sandhu S; Iravani A; Akhurst T; Kong G; Ravi Kumar A; Murphy DG; Williams SG; Hicks RJ; Hofman MS
Eur Urol Oncol; 2019 Nov; 2(6):670-676. PubMed ID: 31412006
[TBL] [Abstract][Full Text] [Related]
17. Prostate-specific membrane antigen-targeted endoradiotherapy in metastatic prostate cancer.
Lawal IO; Bruchertseifer F; Vorster M; Morgenstern A; Sathekge MM
Curr Opin Urol; 2020 Jan; 30(1):98-105. PubMed ID: 31644433
[TBL] [Abstract][Full Text] [Related]
18. Influence of short-term dexamethasone on the efficacy of
Derlin T; Sommerlath Sohns JM; Schmuck S; Henkenberens C; von Klot CAJ; Ross TL; Bengel FM
Prostate; 2020 May; 80(8):619-631. PubMed ID: 32187729
[TBL] [Abstract][Full Text] [Related]
19. Response and Tolerability of a Single Dose of 177Lu-PSMA-617 in Patients with Metastatic Castration-Resistant Prostate Cancer: A Multicenter Retrospective Analysis.
Rahbar K; Schmidt M; Heinzel A; Eppard E; Bode A; Yordanova A; Claesener M; Ahmadzadehfar H
J Nucl Med; 2016 Sep; 57(9):1334-8. PubMed ID: 27056618
[TBL] [Abstract][Full Text] [Related]
20.
Bräuer A; Grubert LS; Roll W; Schrader AJ; Schäfers M; Bögemann M; Rahbar K
Eur J Nucl Med Mol Imaging; 2017 Sep; 44(10):1663-1670. PubMed ID: 28624848
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
